Market Cap | 28.38M | P/E | - | EPS this Y | 14.30% | Ern Qtrly Grth | - |
Income | -40.69M | Forward P/E | -0.79 | EPS next Y | -4.60% | 50D Avg Chg | -7.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -18.00% |
Dividend | N/A | Price/Book | 0.30 | EPS next 5Y | - | 52W High Chg | -45.00% |
Recommedations | 1.40 | Quick Ratio | 15.86 | Shares Outstanding | 20.63M | 52W Low Chg | 14.00% |
Insider Own | 6.13% | ROA | -28.11% | Shares Float | 15.17M | Beta | 1.85 |
Inst Own | 51.36% | ROE | -45.91% | Shares Shorted/Prior | 2.10M/1.88M | Price | 2.51 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 34,432 | Target Price | 26.40 |
Oper. Margin | - | Earnings Date | Nov 1 | Volume | 42,949 | Change | -1.18% |
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.
Oppenheimer | Outperform | Aug 12, 24 |
HC Wainwright & Co. | Buy | Aug 8, 24 |
HC Wainwright & Co. | Buy | May 6, 24 |
Oppenheimer | Outperform | Apr 22, 24 |
HC Wainwright & Co. | Buy | Apr 8, 24 |
HC Wainwright & Co. | Buy | Mar 14, 24 |
HC Wainwright & Co. | Buy | Aug 4, 23 |
HC Wainwright & Co. | Buy | May 8, 23 |
HC Wainwright & Co. | Buy | May 1, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Opaleye Management Inc. | 10% Owner 10% Owner | Dec 30 | Sell | 2.71 | 15,473 | 41,932 | 130,000 | 12/30/22 |
Opaleye Management Inc. | 10% Owner 10% Owner | Sep 14 | Buy | 3.89 | 23,900 | 92,971 | 132,300 | 09/15/22 |
Shefferman Jesse | CEO and President CEO and President | Aug 11 | Buy | 3.84 | 9,065 | 34,810 | 879,441 | 08/15/22 |
Opaleye Management Inc. | 10% Owner 10% Owner | Apr 07 | Buy | 4.77 | 10,136 | 48,349 | 127,500 | 04/15/22 |
BESHAR LUKE M | Director Director | Mar 14 | Buy | 4.25 | 10,000 | 42,500 | 188,000 | 03/16/22 |
BESHAR LUKE M | Director Director | Mar 10 | Buy | 4.4555 | 10,000 | 44,555 | 178,000 | 03/14/22 |
Opaleye Management Inc. | 10% Owner 10% Owner | Dec 28 | Buy | 6.57 | 11,591 | 76,153 | 120,000 | 12/29/21 |
Opaleye Management Inc. | 10% Owner 10% Owner | Dec 23 | Buy | 6.57 | 38,000 | 249,660 | 110,000 | 12/27/21 |
Marshall Randall | - - | Sep 15 | Sell | 19.63 | 2,554 | 50,135 | 585,600 | 09/15/20 |